Efficacy and Safety Trials Results of Complement Inhibitors

EP: 1.PNH Overview and Pathophysiology

EP: 2.Intravascular and Extravascular Hemolysis MoA in PNH

EP: 3.Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming

EP: 4.Key Treatment Considerations for Patients Diagnosed With PNH

EP: 5.Complement System Role in PNH Treatment Approach

EP: 6.Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

EP: 7.Efficacy End Points For PNH Treatment

Now Viewing

EP: 8.Efficacy and Safety Trials Results of Complement Inhibitors

Video content above is prompted by the following:

Several complement inhibitors have been approved since eculizumab, including ravulizumab, a long-acting C5 inhibitor; danicopan, a factor D inhibitor; pegcetacoplan, a complement C3 inhibitor; and iptacopan, a complement factor B inhibitor. Please discuss the efficacy and safety results from the pivotal trials for each of these treatments.